Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$11.50
+6.2%
$9.06
$6.11
$19.00
$1.08B1.995,432 shs165,109 shs
Immutep Limited stock logo
IMMP
Immutep
$1.89
+1.1%
$1.71
$1.32
$3.34
$276.01M1.8220,259 shs172,302 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$24.60
+0.4%
$20.01
$16.16
$26.55
$996.37M0.62195,088 shs343,520 shs
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$6.39
-3.2%
$7.70
$4.25
$16.74
$984.64M-0.921.27 million shs1.23 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
+13.28%+22.93%+44.02%-6.40%-26.92%
Immutep Limited stock logo
IMMP
Immutep
+1.08%-24.90%+28.08%-6.97%-35.07%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
+8.99%+25.45%+40.00%-6.20%+39.60%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
+0.15%-14.62%+16.81%-36.60%+17.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.2601 of 5 stars
0.02.00.00.01.91.70.0
Immutep Limited stock logo
IMMP
Immutep
1.8929 of 5 stars
3.53.00.00.03.10.00.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.6727 of 5 stars
0.83.02.51.13.43.32.5
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
4.3137 of 5 stars
3.51.00.04.82.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
BuyN/AN/A
Immutep Limited stock logo
IMMP
Immutep
3.00
Buy$8.50349.74% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-18.70% Downside
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
3.00
Buy$21.17231.25% Upside

Current Analyst Ratings Breakdown

Latest IMMP, WVE, GYRE, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/29/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/8/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
3/26/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/11/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/5/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/25/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$105.76M10.19$0.23 per share50.49$0.18 per share63.89
Immutep Limited stock logo
IMMP
Immutep
$5.14M53.70N/AN/A$1.05 per share1.80
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.90$2.26 per share10.87$6.09 per share4.04
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$108.30M9.09N/AN/A$0.40 per share15.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M$0.02575.00N/A-84.57%-118.43%-71.97%N/A
Immutep Limited stock logo
IMMP
Immutep
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.7851.2511.710.451.75%25.35%6.21%N/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%N/A

Latest IMMP, WVE, GYRE, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.03$0.03N/AN/A$28.40 million$22.06 million
5/8/2025Q1 2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
3/17/2025Q4 2024
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.04$0.01-$0.03$0.02$23.50 million$27.87 million
3/4/2025Q4 2024
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.17$0.17+$0.34$0.17$25.60 million$83.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Immutep Limited stock logo
IMMP
Immutep
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.481.95%N/A61.54%N/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/AN/AN/AN/AN/A

Latest IMMP, WVE, GYRE, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
3.72
3.29
Immutep Limited stock logo
IMMP
Immutep
0.01
18.25
18.25
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/A
1.90
1.90

Institutional Ownership

CompanyInstitutional Ownership
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Immutep Limited stock logo
IMMP
Immutep
2.32%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
19.52%
Immutep Limited stock logo
IMMP
Immutep
3.07%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
29.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4093.74 million75.27 millionNo Data
Immutep Limited stock logo
IMMP
Immutep
2,021146.04 million141.09 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
240154.09 million108.14 millionOptionable

Recent News About These Companies

StockNews.com Downgrades Wave Life Sciences (NASDAQ:WVE) to Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$11.50 +0.67 (+6.19%)
As of 04:00 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Immutep stock logo

Immutep NASDAQ:IMMP

$1.89 +0.02 (+1.07%)
As of 04:00 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$24.60 +0.10 (+0.41%)
As of 04:00 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Wave Life Sciences stock logo

Wave Life Sciences NASDAQ:WVE

$6.39 -0.21 (-3.18%)
As of 04:00 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.